These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26197757)

  • 1. [Search for Factors Related to Vascular Pain Expression upon Administration of Oxaliplatin into a Peripheral Vein].
    Takagi A; Yonemoto N; Aoyama Y; Touma Y; Kajiwara M; Watanabe K; Miyazaki Y; Koinuma M
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):887-9. PubMed ID: 26197757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain.
    Kawazoe H; Sumikawa S; Nakauchi K; Yakushijin Y; Yamamoto Y; Watanabe Y; Tanaka A; Araki H
    Int J Clin Pharm; 2017 Dec; 39(6):1291-1297. PubMed ID: 29027645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of 5% glucose solution and dexamethasone and oxaliplatin-related vascular pain grade: a case study.
    Okada Y; Kajiume S; Taniguchi T; Kimoto S; Ogawa Y; Kiba T
    Clin J Oncol Nurs; 2013 Oct; 17(5):554-5. PubMed ID: 24080056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Etiology and management of venous pain during intravenous administration of oxaliplatin].
    Matsuyama K; Mishima H; Ueno H; Kajihara K; Morioka A; Morimoto S; Yamauchi K; Honda Y; Komori K; Tsujinaka T
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):411-4. PubMed ID: 21403443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigating the incidence of injection-site reactions associated with administration of oxaliplatin into a peripheral vein and management local adverse reactions].
    Hibi S; Tatematsu M; Nishio S; Miyatani M; Tosaki K; Ohara M; Maeda T; Tomita N; Kawai M; Ina K; Oishi K; Muro K
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1447-52. PubMed ID: 21918339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain.
    Nagao S; Furihata M; Fukagawa K; Furihata T; Matsuhashi Y; Wada T
    J Infect Chemother; 2017 Jul; 23(7):493-497. PubMed ID: 28285948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reduction of angialgia during peripheral administration of oxaliplatin mixed with dexamethasone].
    Shiotsuka Y; Uebuchi M; Hamada S; Morita N; Moriyama A; Yamashita M; Ichikawa Y; Fujii H; Matsuo A; Kuhara H; Ikuta Y; Ikeshima S; Kuramoto M; Fujii K; Shimada S
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1583-6. PubMed ID: 23064078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
    Takahashi M; Hasegawa K; Oba M; Saiura A; Arita J; Sakamoto Y; Shinozaki E; Mizunuma N; Matsuyama Y; Kokudo N
    Invest New Drugs; 2016 Aug; 34(4):468-73. PubMed ID: 27155613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
    Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y
    Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tolerability of Oxaliplatin-Based Adjuvant Chemotherapy for Patients with Colorectal Cancer].
    Matsuo H; Nakanishi M; Arita T; Murayama Y; Kuriu Y; Kosuga T; Konishi H; Morimura R; Komatsu S; Shiozaki A; Ikoma H; Ichikawa D; Fujiwara H; Okamoto K; Otsuji E
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2112-4. PubMed ID: 26805281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin.
    Yamauchi H; Goto T; Takayoshi K; Sagara K; Uoi M; Kawanabe C; Matsunaga M; Miyoshi T; Uchino K; Misumi N; Nishino T
    Eur J Cancer Care (Engl); 2015; 24(1):111-6. PubMed ID: 24304429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
    Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
    Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of local reactions to oxaliplatin infusions by peripheral versus central venous administration.
    To YY; Sutcliffe KJ; Hoen HM; Swaney RA; Nicholls JD; Crocenzi TS
    J Oncol Pharm Pract; 2016 Apr; 22(2):256-60. PubMed ID: 25762052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.
    Wang XS; Shi Q; Dougherty PM; Eng C; Mendoza TR; Williams LA; Fogelman DR; Cleeland CS
    Oncology; 2016; 90(3):127-35. PubMed ID: 26882477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin infusion-related venous pain: prevention by simultaneous intravenous fluids.
    van Ravensteijn S; van Merrienboer B; van Asten S; Pruijt J; Hilbink M; Tol J
    BMJ Support Palliat Care; 2021 Jun; 11(2):226-229. PubMed ID: 32451327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.